Skip to content

Migraine in Electrohypersensitive Patients

Prevalence of Migraine Disease in Electrohypersensitive Patients

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04845152
Enrollment
317
Registered
2021-04-14
Start date
2021-04-30
Completion date
2022-01-30
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Headache, Migraine

Keywords

Electrohypersensitivity

Brief summary

The investigators propose here by the use of the French version of the migraine disease screening questionnaire (ID Migraine ™) to study the prevalence of migraine disease in a population of electrohypersensitive patients

Interventions

None listed

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Informed Consent * 18 years or older at the time of informed consent With all these criteria : * the perception by the subjects of various non-specific functional symptoms * the absence of clinical and biological evidence to explain the symptoms * the attribution by the subjects themselves of these symptoms to exposure to electromagnetic fields, which are themselves diverse * the symptoms are chronic (more than 3 months) * the symptoms appear during an exposure to a source of electromagnetic radiation and cease after the exposure is stopped * the symptoms are reproducible

Exclusion criteria

\- age under 18 years old

Design outcomes

Primary

MeasureTime frameDescription
Possible migraine attack12 monthsWith the number of positive response to the French version of the migraine disease screening questionnaire, we are looking for the patients declaring themselves electrohypersensitive if they have had headaches in the last 12 months with characteristics that could evoke a migraine attack.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026